280 related articles for article (PubMed ID: 25213036)
1. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
[TBL] [Abstract][Full Text] [Related]
2. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Duarte R; Richardson M; Nevitt S; Boland A; Kotas E; McEntee J; Thorp N
Pharmacoecon Open; 2019 Sep; 3(3):293-302. PubMed ID: 30742256
[TBL] [Abstract][Full Text] [Related]
3. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Lopes G; Glück S; Avancha K; Montero AJ
Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
[TBL] [Abstract][Full Text] [Related]
4. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
5. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Cortes J; O'Shaughnessy J; Loesch D; Blum JL; Vahdat LT; Petrakova K; Chollet P; Manikas A; Diéras V; Delozier T; Vladimirov V; Cardoso F; Koh H; Bougnoux P; Dutcus CE; Seegobin S; Mir D; Meneses N; Wanders J; Twelves C;
Lancet; 2011 Mar; 377(9769):914-23. PubMed ID: 21376385
[TBL] [Abstract][Full Text] [Related]
6. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
7. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
9. Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Fleeman N; Bagust A; Beale S; Dwan K; Dickson R; Proudlove C; Dundar Y
Pharmacoeconomics; 2015 Jan; 33(1):13-23. PubMed ID: 25138171
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Dickson R; Bagust A; Boland A; Blundell M; Davis H; Dundar Y; Hockenhull J; Martin Saborido C; Oyee J; Ramani VS
Pharmacoeconomics; 2011 Dec; 29(12):1051-62. PubMed ID: 21967156
[TBL] [Abstract][Full Text] [Related]
12. Eribulin mesylate for the treatment of patients with refractory metastatic breast cancer: use of a "physician's choice" control arm in a randomized approval trial.
Donoghue M; Lemery SJ; Yuan W; He K; Sridhara R; Shord S; Zhao H; Marathe A; Kotch L; Jee J; Wang Y; Zhou L; Adams WM; Jarral V; Pilaro A; Lostritto R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2012 Mar; 18(6):1496-505. PubMed ID: 22282463
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancer.
Chabot I; Zhao Q; Su Y
Curr Med Res Opin; 2020 Dec; 36(12):2025-2036. PubMed ID: 33044090
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal.
Rafia R; Simpson E; Stevenson M; Papaioannou D
Pharmacoeconomics; 2013 Jun; 31(6):471-8. PubMed ID: 23568332
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
Beale S; Dickson R; Bagust A; Blundell M; Dundar Y; Boland A; Marshall E; Plummer R; Proudlove C
Pharmacoeconomics; 2013 Dec; 31(12):1121-9. PubMed ID: 24114739
[TBL] [Abstract][Full Text] [Related]
16. Costs associated with Eribulin treatment for patients with metastatic breast cancer in a comprehensive cancer center in France.
Hurtaud A; Donnadieu A; Escalup L; Cottu PH; Baffert S
Breast; 2016 Dec; 30():73-79. PubMed ID: 27639032
[TBL] [Abstract][Full Text] [Related]
17. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Stevenson M; Simpson E; Harvey R; Stevens J
Pharmacoeconomics; 2016 Jul; 34(7):673-80. PubMed ID: 26892972
[TBL] [Abstract][Full Text] [Related]
19. Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Harnan S; Ren S; Thokala P; Wong R; Mukuria C; Green C; Pledge S; Tidy J
Pharmacoeconomics; 2017 Jan; 35(1):97-109. PubMed ID: 27506954
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
Paillard MJ; Curtit E; Dobi E; Mansi L; Bazan F; Villanueva C; Chaigneau L; Montcuquet P; Meneveau N; Thiery-Vuillemin A; Nerich V; Pivot X
Bull Cancer; 2015 Sep; 102(9):737-48. PubMed ID: 26022285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
